A Randomized, Open-Label, Multicenter, Phase II Trial Evaluating the Safety and Activity of DNIB0600A Compared to Pegylated Liposomal Doxorubicin Administered Intravenously to Patients With Platinum-Resistant Ovarian Cancer
Phase of Trial: Phase II
Latest Information Update: 29 Aug 2017
At a glance
- Drugs Lifastuzumab vedotin (Primary) ; Doxorubicin liposomal
- Indications Fallopian tube cancer; Ovarian cancer; Peritoneal cancer
- Focus Therapeutic Use
- Sponsors Genentech
- 16 Feb 2017 Status changed from active, no longer recruiting to completed.
- 23 Nov 2016 This trial was completed in Poland (end date: 2016-08-17), according to European Clinical Trials Database.
- 20 Sep 2016 This trial is completed in Belgium.